JPWO2020152361A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020152361A5 JPWO2020152361A5 JP2021543144A JP2021543144A JPWO2020152361A5 JP WO2020152361 A5 JPWO2020152361 A5 JP WO2020152361A5 JP 2021543144 A JP2021543144 A JP 2021543144A JP 2021543144 A JP2021543144 A JP 2021543144A JP WO2020152361 A5 JPWO2020152361 A5 JP WO2020152361A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compounds
- pharmaceutically acceptable
- substituted
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 205
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 85
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 49
- 208000035475 disorder Diseases 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 39
- 239000012453 solvate Substances 0.000 claims description 39
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 35
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 28
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 26
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 22
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 17
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 108010034143 Inflammasomes Proteins 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 8
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 8
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- -1 C 6 aryl Chemical group 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 4
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 230000003959 neuroinflammation Effects 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000007153 proteostasis deficiencies Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 22
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 8
- 201000003274 CINCA syndrome Diseases 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796724P | 2019-01-25 | 2019-01-25 | |
| US62/796,724 | 2019-01-25 | ||
| PCT/EP2020/051836 WO2020152361A1 (en) | 2019-01-25 | 2020-01-24 | Carbamate derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518526A JP2022518526A (ja) | 2022-03-15 |
| JP2022518526A5 JP2022518526A5 (https=) | 2023-01-31 |
| JPWO2020152361A5 true JPWO2020152361A5 (https=) | 2023-01-31 |
Family
ID=69375331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543144A Pending JP2022518526A (ja) | 2019-01-25 | 2020-01-24 | カルバメート誘導体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220098159A1 (https=) |
| EP (1) | EP3914351A1 (https=) |
| JP (1) | JP2022518526A (https=) |
| KR (1) | KR20210131329A (https=) |
| CN (1) | CN113660983A (https=) |
| AU (1) | AU2020211361A1 (https=) |
| BR (1) | BR112021014389A2 (https=) |
| CA (1) | CA3126495A1 (https=) |
| EA (1) | EA202192057A1 (https=) |
| IL (1) | IL284843A (https=) |
| MX (1) | MX2021008930A (https=) |
| SG (1) | SG11202107653RA (https=) |
| WO (1) | WO2020152361A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FI921595A7 (fi) * | 1991-04-17 | 1992-10-18 | American Home Prod | Rapamysiinikarbamaatteja |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO1999012534A1 (en) * | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| US20020002200A1 (en) * | 2000-02-04 | 2002-01-03 | Bishwagit Nag | Novel diphenylethylene compounds |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| WO2017035413A2 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| JP2019512009A (ja) * | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| RU2720203C1 (ru) * | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
-
2020
- 2020-01-24 BR BR112021014389-0A patent/BR112021014389A2/pt not_active Application Discontinuation
- 2020-01-24 KR KR1020217025978A patent/KR20210131329A/ko not_active Abandoned
- 2020-01-24 JP JP2021543144A patent/JP2022518526A/ja active Pending
- 2020-01-24 EA EA202192057A patent/EA202192057A1/ru unknown
- 2020-01-24 WO PCT/EP2020/051836 patent/WO2020152361A1/en not_active Ceased
- 2020-01-24 US US17/425,461 patent/US20220098159A1/en not_active Abandoned
- 2020-01-24 SG SG11202107653RA patent/SG11202107653RA/en unknown
- 2020-01-24 CA CA3126495A patent/CA3126495A1/en active Pending
- 2020-01-24 EP EP20702596.6A patent/EP3914351A1/en not_active Withdrawn
- 2020-01-24 CN CN202080024041.8A patent/CN113660983A/zh active Pending
- 2020-01-24 MX MX2021008930A patent/MX2021008930A/es unknown
- 2020-01-24 AU AU2020211361A patent/AU2020211361A1/en not_active Abandoned
-
2021
- 2021-07-14 IL IL284843A patent/IL284843A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115066418B (zh) | 具有抗炎性质的羧基衍生物 | |
| HRP20250964T1 (hr) | Derivati sulfonil ureje kao modulatori nlrp3 inflamasoma | |
| TWI851542B (zh) | Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑 | |
| JP2020529405A5 (https=) | ||
| ES2398606T3 (es) | Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio | |
| JP2018510207A5 (https=) | ||
| ES2228557T3 (es) | Aminobenzofenonas con inhibidores de la il-1beta y tnf-alfa. | |
| HRP20200214T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| JP2020520984A (ja) | 新規な化合物及び使用 | |
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use | |
| EP2307362A2 (en) | Antagonists of prostaglandin d2 receptors | |
| JP2002539187A (ja) | アミド誘導体 | |
| GB2474120A (en) | 5-Biphenylisoxazole derivatives as lysophosphatidic acid receptor antagonists | |
| KR20040010713A (ko) | 페닐피리딘 카보닐 피페라진 유도체 | |
| JP2018531289A5 (https=) | ||
| JP2005538099A5 (https=) | ||
| JP2013526520A5 (https=) | ||
| JP7617165B2 (ja) | 炎症性気道疾患の治療のためのオートタキシン（ａｔｘ）モジュレーターとしての１－（６－（メトキシ）ピリダジン－３－イル）シクロプロパン－１－カルボキサミド誘導体 | |
| CN103635466A (zh) | 芳族酰胺及其用途 | |
| JP6413032B2 (ja) | 新規ｄｇａｔ２阻害剤 | |
| WO2005102389A2 (en) | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists | |
| JP7614646B2 (ja) | 呼吸器疾患の処置のための化合物及び組成物 | |
| CN104507906A (zh) | 新的ep2受体激动剂 | |
| JP7796047B2 (ja) | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン | |
| CA2796826A1 (en) | Bifunctional quinoline derivatives |